1-(2-Methylsulfanylpyrimidin-4-yl)-4-(4-methylsulfonylpiperazin-1-yl)indole | 1438899-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2-Methylsulfanylpyrimidin-4-yl)-4-(4-methylsulfonylpiperazin-1-yl)indole
• 英文别名: 1-(2-methylsulfanylpyrimidin-4-yl)-4-(4-methylsulfonylpiperazin-1-yl)indole
• CAS: 1438899-33-2
• 化学式: C₁₈H₂₁N₅O₂S₂
• 分子量: 403.529
• InChiKey: BNJVVWHAWCJEMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(2-Methylsulfanylpyrimidin-4-yl)-4-(4-methylsulfonylpiperazin-1-yl)indole 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-(4-Methylsulfonylpiperazin-1-yl)-1-(2-methylsulfonylpyrimidin-4-yl)indole
  参考文献：
  名称：

  Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): Optimization for JNK potency and physicochemical properties

  摘要：

  A novel series of indole/indazole-aminopyrimidines was designed and synthesized with an aim to achieve optimal potency and selectivity for the c-Jun kinase family or JNKs. Structure guided design was used to optimize the series resulting in a significant potency improvement. The best compound (17) has IC50 of 3 nM for JNK1 and 20 nM for JNK2, with greater than 40-fold selectivity against other kinases with good physicochemical and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.029
• 作为产物：
  描述：

  4-溴吲哚 在 bis(tri-tert-butylphosphine)palladium(0) 、 sodium hydride 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(2-Methylsulfanylpyrimidin-4-yl)-4-(4-methylsulfonylpiperazin-1-yl)indole
  参考文献：
  名称：

  Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): Optimization for JNK potency and physicochemical properties

  摘要：

  A novel series of indole/indazole-aminopyrimidines was designed and synthesized with an aim to achieve optimal potency and selectivity for the c-Jun kinase family or JNKs. Structure guided design was used to optimize the series resulting in a significant potency improvement. The best compound (17) has IC50 of 3 nM for JNK1 and 20 nM for JNK2, with greater than 40-fold selectivity against other kinases with good physicochemical and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.029